Acco Group Holdings Ltd ACCL
Last close
—
Market cap
—
52-week range
— - —
No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.
Valuation FY2025 figures against the last close
P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS0.08
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $4.9M | $4.4M | $3.7M | — |
| Cost of revenue | $2.5M | $2.0M | $1.8M | — |
| Gross profit | $2.1M | $2.1M | $1.7M | — |
| SG&A | $654.7K | $522.0K | $708.3K | — |
| Total operating expenses | $1.1M | $1.1M | $1.3M | — |
| Operating income | $1.1M | $1.1M | $482.2K | — |
| Pre-tax income | $1.2M | $1.1M | $692.2K | — |
| Income tax | $130.5K | $127.2K | $50.3K | — |
| Net income | $1.0M | $992.8K | $641.9K | — |
| EPS, basic | 0.08 | 0.08 | 0.05 | — |
| EPS, diluted | 0.08 | 0.08 | 0.05 | — |
| Shares, diluted (wtd. avg.) | $12.5M | $12.5M | $12.5M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $2.5M | $1.1M | $1.8M | $2.2M |
| Receivables | $293.6K | $245.5K | — | — |
| Total current assets | $2.9M | $2.6M | — | — |
| Property, plant and equipment | $27.6K | $14.7K | — | — |
| Total assets | $3.9M | $2.7M | — | — |
| Accounts payable | $38.0K | $19.3K | — | — |
| Total current liabilities | $1.6M | $1.5M | — | — |
| Total liabilities | $1.7M | $1.5M | — | — |
| Retained earnings | $2.1M | $1.1M | — | — |
| Total equity | $2.2M | $1.1M | $2.1M | $2.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | $1.5M | $1.1M | $742.0K | — |
| Depreciation and amortisation | $10.3K | $9.3K | — | — |
| Capital expenditure | $23.2K | $1.3K | $7.7K | — |
| Investing cash flow | -$23.2K | -$1.3K | -$7.7K | — |
| Financing cash flow | -$1.1M | -$882.8K | -$1.1M | — |
| Dividends paid | — | — | $51.9K | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-25-111270.
Others in SIC 8742
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| BAH | Booz Allen Hamilton Holding Corp | $8.76B | 10.6x | -6.4% |
| G | Genpact LTD | $6.27B | 11.9x | 6.6% |
| FCN | FTI CONSULTING, INC | $4.19B | 18.4x | 2.4% |
| EXPO | EXPONENT INC | $3.25B | 33.0x | 4.2% |
| HURN | Huron Consulting Group Inc. | $2.52B | 26.6x | 11.9% |
| ASTH | Astrana Health, Inc. | $2.14B | 83.6x | 56.4% |
| ICFI | ICF International, Inc. | $1.58B | 17.8x | -7.3% |
| BWMN | Bowman Consulting Group Ltd. | $735.5M | 58.1x | 14.9% |